Role and Mechanism of Maresin-1 in Acute Lung Injury Induced by Trauma-Hemorrhagic Shock

Med Sci Monit. 2020 Aug 4:26:e923518. doi: 10.12659/MSM.923518.

Abstract

BACKGROUND It is reported that trauma hemorrhagic shock (THS) could resulted in organ injury and is related to a high mortality rate. Maresin-1 (MaR1), a derived medium through biosynthesis, is involved in inflammatory responses. However, the mechanism of MaR1 against acute lung injury needs to be further understood. This report aimed to explore whether MaR1 had a protective effect on lung injury. MATERIAL AND METHODS We constructed a THS-induced acute lung damage rat model and then treated the rats with MaR1. We determined Evan's blue dye (EBD) lung permeability, lung permeability index, wet/dry (W/D) weight ratio, nitric oxide (NO) concentration and inducible nitric oxide synthase (iNOS) expression in lung tissue samples. The inflammation-related cytokines levels in the bronchoalveolar lavage fluid (BALF) and serum of rats were determined by enzyme-linked immunosorbent assay (ELISA). Finally, the TLR4/p38MAPK/NF-kappaB pathway was analyzed by quantitative real-time polymerase chain reaction and western blot assay. RESULTS The increased EBD ratio, lung permeability index and W/D weight ratio, NO concentration and iNOS levels were suppressed by MaR1 treatment. THS-induced over-production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in BALF and serum was suppressed by MaR1. Besides, the TLR4/p38MAPK/NF-kappaB pathway activation in THS-induced rats were inhibited by MaR1 treatment. CONCLUSIONS Our study showed that MaR1 could effectively alleviated THS-induced lung injury via inhibiting the excitation of the TLR4/p38MAPK/NF-kappaB pathway in THS-induced rats, suggesting that MaR1 might be a novel agent for lung damage treatment.

MeSH terms

  • Acute Lung Injury / blood
  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / etiology*
  • Animals
  • Bronchoalveolar Lavage Fluid / chemistry
  • Cytokines / blood
  • Disease Models, Animal
  • Docosahexaenoic Acids / therapeutic use*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Male
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Protective Agents / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Shock, Hemorrhagic / complications*
  • Signal Transduction / drug effects
  • Toll-Like Receptor 4 / metabolism
  • Treatment Outcome
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
  • Cytokines
  • NF-kappa B
  • Protective Agents
  • Tlr4 protein, rat
  • Toll-Like Receptor 4
  • Docosahexaenoic Acids
  • Nitric Oxide
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • p38 Mitogen-Activated Protein Kinases